Glatiramer
Gynecologic Cancer
Institut du Cancer de Montpellier - Val d'Aurelleprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
33 Active assets in the Gynecologic Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ringer's acetate Joachim Zdolsek | Phase 4 | B |
Nivolumab Clovis Oncology, Inc. | Phase 2 | B |
FENTANYL RenJi Hospital | Phase 4 | B |
DROPERIDOL RenJi Hospital | Phase 4 | B |
NORMAL HUMAN SERUM ALBUMIN Joachim Zdolsek | Phase 4 | B |
View all 41 →
Same molecule, other indications
Glatiramer is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →